Last $1.54 USD
Change Today +0.02 / 1.32%
Volume 743.1K
DVAX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert L. Coffman Ph.D.

Chief Scientific Officer and Vice President, Dynavax Technologies Corporation
AgeTotal Calculated CompensationThis person is connected to 14 board members in 1 different organizations across 3 different industries.

See Board Relationships
67$963,634
As of Fiscal Year 2013

Background*

Dr. Robert L. Coffman, Ph.D. has been Vice President and Chief Scientific Officer at Dynavax Technologies Corporation since December 2000. Dr. Coffman has been Member of Scientific Advisory Board at Genocea Biosciences, Inc., since November 23, 2009. He joined Dynavax Technologies Corporation from the DNAX Research Institute where he had been since 1981, as Distinguished Research Fellow. Dr. Coffman has made fundamental discoveries about the regulation of immune responses ...

Read Full Background

Corporate Headquarters*

2929 Seventh Street
Berkeley, California 94710

United States

Phone: 510-848-5100
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BA
Indiana University, Bloomington
PhD
University of California - San Diego

Other Affiliations*

Annual Compensation*

Salary$282,620
Total Annual Compensation$282,620

Stock Options*

All Other Compensation$250
Exercisable Options792,916
Exercisable Options Value$144,500
Unexercisable Options282,084
Total Value of Options$144,500
Total Number of Options1,075,000

Total Compensation*

Total Annual Cash Compensation$457,870
Total Short Term Compensation$282,620
Other Long Term Compensation$250
Total Calculated Compensation$963,634
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $1.54 USD +0.02

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
J. Joseph Kim Ph.D.Chief Executive Officer, President, Director and Member of Finance Committee
Inovio Pharmaceuticals, Inc.
$852.8K
Vijay B. Samant Chief Executive Officer, President, Acting Chief Financial Officer and Director
Vical Incorporated
$557.0K
Steven W. King Chief Executive Officer, President, Director, Chief Executive Officer of Avid Bioservices Inc and President of Avid Bioservices Inc
Peregrine Pharmaceuticals, Inc.
$445.8K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Jonathan J. Lewis M.D., Ph.D.Chief Executive Officer and Director
ZIOPHARM Oncology, Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.